Production of extracellular vesicles from muscle cells

Prof. Shulamit Levenberg | Biomedical Engineering


Pharmaceuticals and Biotechnology

The Technology

Exosomes, a subtype of extracellular vesicles, are nanometer vesicles (about 30-150 nm in diameter) secreted from cell membrane, carrying various cargos, including genetic materials, proteins and lipids, for conducting intercellular communications. Several studies showed the beneficial effects of exosomes-based therapies in skeletal and cardiac muscle regeneration using both in vitro and in vivo models. In vitro, exosomes-treated myoblasts expressed faster and higher differentiation rates, and exosomes-treated endothelial cells had an increase in vessel formation. Exosomes-based therapies hold great potential to evoke rapid market shift toward this promising acellular novel technology, with expected market growth to over 200 million dollars in the coming years). This expected increase in demands will require the development of new scalable and efficient methodologies for exosome production from wide range of cell types, specifically from human muscle cells (skeletal or cardiac) in order to treat muscle injuries. However, the common protocols for exosomes production mainly based on 2D static platform which do not mimic the 3D physiological dynamic conditions (cyclic loading) and limited in their yield. The invention is a methodology for exosome production from human muscle cells that will overcome these limitations. It enables to design and fabricate 3D stretchable scaffold with 3 favorable fiber orientation for muscle-forming cells to attach, proliferate, and differentiate towards mature muscle cells.


  • Higher production efficiency of EVs from muscle origin.
  • Cultivation under 3D dynamic physiological conditions for optimizing EVs biological properties from muscle origin.
  • Scaled up and fit commercial bioreactors for mass production of muscle origin exosomes.
  • Natural, chemicals free, cultivation protocols for safe, off-the-shelf, EVs production


  • Large scale, off-the-shelf, exosomes production for research and therapeutic purposes (11- fold higher values in yield).
  • EVs from muscle origin can induce muscle regeneration in major skeletal muscle injuries and heart regeneration post myocardial infraction.
arrow Business Development Contacts
Dr. Gal Gur
Director of Business Development, Life Sciences